Next Questions in CLL in 2020: Is Ibrutinib the Best BTK Inhibitor? Is BTK/Ven Combo Better Than Ven-Obin Alone? Will Stopping Therapy Avoid Resistance and Allow Retreatment?

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

Next Questions in CLL in 2020: Is Ibrutinib the Best BTK Inhibitor? Is BTK/Ven Combo Better Than Ven-Obin Alone? Will Stopping Therapy Avoid Resistance and Allow Retreatment?

By Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020) FEATURING Jennifer Brown

313 views

October 29, 2020

SOHO 2020 on-demand content is available through January 12, 2021. To access the virtual environment, ...
read more ↘ resources and on-demand webinars, go to https://soho.click/register.
↖ read less

0 Comments

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Feat. R. Gale